Syncona has one of the largest and highest quality gene therapy platforms globally with the potential to deliver dramatic efficacy across the tens of thousands of known genetic diseases.
The Syncona team has built companies targeting genetic diseases in the key tissue compartments where gene therapy has shown dramatic patient impact. These include: the retina, the liver, the central nervous system and kidney. Our ambition is ultimately to address the most prevalent diseases in each tissue compartment.
value of gene therapy portfolio
number of clinical trials
financing rounds in previous financial year
Latest Gene Therapy insights
*Unless stated all financials at 30 June 2021